首页 > 最新文献

Melanoma Management最新文献

英文 中文
Increase of sentinel lymph node melanoma staging in The Netherlands: still room and need for further improvement. 荷兰前哨淋巴结黑色素瘤分期增加:仍有进一步改善的空间和需要。
IF 3.6 Q4 ONCOLOGY Pub Date : 2020-12-14 DOI: 10.2217/mmt-2020-0018
Harmanjit Singh, Anjelli Wignakumar, Georgina J Williams, Shima Jamshidi, Daniel P Butler, Simon H Wood, Navid Jallali, Jonathan A Dunne
Harmanjit Singh‡ ,1, Anjelli Wignakumar‡ ,1, Georgina J Williams2, Shima Jamshidi3, Daniel P Butler2, Simon H Wood2, Navid Jallali2 & Jonathan A Dunne*,2 1Imperial College School of Medicine, Kensington, London SW7 2DD, UK 2Department of Plastic Surgery, Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham Palace Rd, Hammersmith, London W6 8RF, UK 3Department of Plastic Surgery, Royal Free London NHS Foundation Trust, Pond St, Hampstead, London NW3 2QG, UK *Author for correspondence: jonathan.dunne1@nhs.net ‡Joint first authors
{"title":"Increase of sentinel lymph node melanoma staging in The Netherlands: still room and need for further improvement.","authors":"Harmanjit Singh, Anjelli Wignakumar, Georgina J Williams, Shima Jamshidi, Daniel P Butler, Simon H Wood, Navid Jallali, Jonathan A Dunne","doi":"10.2217/mmt-2020-0018","DOIUrl":"https://doi.org/10.2217/mmt-2020-0018","url":null,"abstract":"Harmanjit Singh‡ ,1, Anjelli Wignakumar‡ ,1, Georgina J Williams2, Shima Jamshidi3, Daniel P Butler2, Simon H Wood2, Navid Jallali2 & Jonathan A Dunne*,2 1Imperial College School of Medicine, Kensington, London SW7 2DD, UK 2Department of Plastic Surgery, Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham Palace Rd, Hammersmith, London W6 8RF, UK 3Department of Plastic Surgery, Royal Free London NHS Foundation Trust, Pond St, Hampstead, London NW3 2QG, UK *Author for correspondence: jonathan.dunne1@nhs.net ‡Joint first authors","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"8 1","pages":"MMT52"},"PeriodicalIF":3.6,"publicationDate":"2020-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/29/mmt-08-52.PMC7849948.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25343684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Letter in reply: increase of sentinel lymph node melanoma staging in The Netherlands; still room and need for further improvement. 回信:荷兰前哨淋巴结黑色素瘤分期的增加;仍有进一步改进的空间和必要。
IF 1 Q4 ONCOLOGY Pub Date : 2020-11-23 DOI: 10.2217/mmt-2020-0021
Eric A Deckers, Marieke Wj Louwman, Schelto Kruijff, Harald J Hoekstra
{"title":"Letter in reply: increase of sentinel lymph node melanoma staging in The Netherlands; still room and need for further improvement.","authors":"Eric A Deckers, Marieke Wj Louwman, Schelto Kruijff, Harald J Hoekstra","doi":"10.2217/mmt-2020-0021","DOIUrl":"10.2217/mmt-2020-0021","url":null,"abstract":"","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"8 1","pages":"MMT53"},"PeriodicalIF":1.0,"publicationDate":"2020-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/58/mmt-08-53.PMC7849923.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25343685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The challenge of primary gastric melanoma: a systematic review. 原发性胃黑色素瘤的挑战:系统综述。
IF 1 Q4 ONCOLOGY Pub Date : 2020-11-23 DOI: 10.2217/mmt-2020-0009
Gregory S Mellotte, Diya Sabu, Mary O'Reilly, Ray McDermott, Anthony O'Connor, Barbara M Ryan

Aim: Primary gastric melanoma is a rare clinical presentation. The purpose of this review was to compare the 1-year survival in patients who underwent surgery with patients who did not receive treatment.

Patients & methods: A systematic search of databases for case reports and case series of primary gastric melanoma was conducted.

Results: The mean survival of patients was 22 months. One-year survival was 56.5% with surgery, rising to 66% with adjuvant therapy. Mean survival of the surgical group was 21.05 months (±20.2) versus 4.5 months (±3.61) in the nonsurgical group.

Conclusion: Primary gastric melanoma has a poor prognosis but early surgical intervention can have a significant impact on patient outcome. We reviewed the biology and clinical diagnosis of gastrointestinal melanoma and the current management options available.

目的:原发性胃黑色素瘤是一种罕见的临床表现。本综述旨在比较接受手术和未接受治疗的患者的 1 年生存率:对数据库中有关原发性胃黑色素瘤的病例报告和系列病例进行了系统检索:患者的平均生存期为22个月。手术组的一年生存率为 56.5%,辅助治疗组的一年生存率上升至 66%。手术组的平均生存期为21.05个月(±20.2)个月,而非手术组为4.5个月(±3.61)个月:原发性胃黑色素瘤预后较差,但早期手术干预对患者预后有显著影响。我们回顾了胃肠道黑色素瘤的生物学特性和临床诊断,以及目前可用的治疗方案。
{"title":"The challenge of primary gastric melanoma: a systematic review.","authors":"Gregory S Mellotte, Diya Sabu, Mary O'Reilly, Ray McDermott, Anthony O'Connor, Barbara M Ryan","doi":"10.2217/mmt-2020-0009","DOIUrl":"10.2217/mmt-2020-0009","url":null,"abstract":"<p><strong>Aim: </strong>Primary gastric melanoma is a rare clinical presentation. The purpose of this review was to compare the 1-year survival in patients who underwent surgery with patients who did not receive treatment.</p><p><strong>Patients & methods: </strong>A systematic search of databases for case reports and case series of primary gastric melanoma was conducted.</p><p><strong>Results: </strong>The mean survival of patients was 22 months. One-year survival was 56.5% with surgery, rising to 66% with adjuvant therapy. Mean survival of the surgical group was 21.05 months (±20.2) versus 4.5 months (±3.61) in the nonsurgical group.</p><p><strong>Conclusion: </strong>Primary gastric melanoma has a poor prognosis but early surgical intervention can have a significant impact on patient outcome. We reviewed the biology and clinical diagnosis of gastrointestinal melanoma and the current management options available.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"7 4","pages":"MMT51"},"PeriodicalIF":1.0,"publicationDate":"2020-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/2a/mmt-07-51.PMC7724652.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38709863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of intratumoral lymphocyte-to-monocyte ratio and M0 macrophage enrichment in tumor immune microenvironment of melanoma. 瘤内淋巴细胞/单核细胞比值及M0巨噬细胞富集对黑色素瘤肿瘤免疫微环境的预后价值。
IF 1 Q4 ONCOLOGY Pub Date : 2020-11-02 DOI: 10.2217/mmt-2020-0019
Neil K Jairath, Mark W Farha, Ruple Jairath, Paul W Harms, Lam C Tsoi, Trilokraj Tejasvi

Skin cutaneous melanoma is characterized by significant heterogeneity in its molecular, genomic and immunologic features. Whole transcriptome RNA sequencing data from The Cancer Genome Atlas of skin cutaneous melanoma (n = 328) was utilized. CIBERSORT was used to identify immune cell type composition, on which unsupervised hierarchical clustering was performed. Analysis of overall survival was performed using Kaplan-Meier estimates and multivariate Cox regression analyses. Membership in the lymphocyte:monocytelow, monocytehi gh and M0high cluster was an independently poor prognostic factor for survival (HR: 3.03; 95% CI: 1.12-8.20; p = 0.029) and correlated with decreased predicted response to immune checkpoint blockade. In conclusion, an M0-macrophage-enriched, lymphocyte-to-monocyte-ratio-low phenotype in the primary melanoma tumor site independently characterizes an aggressive phenotype that may differentially respond to treatment.

皮肤黑色素瘤在其分子、基因组和免疫特征上具有显著的异质性。利用皮肤黑色素瘤癌症基因组图谱(n = 328)的全转录组RNA测序数据。利用CIBERSORT识别免疫细胞类型组成,并对其进行无监督分层聚类。总生存率分析采用Kaplan-Meier估计和多变量Cox回归分析。属于淋巴细胞:单核细胞低、单核细胞高和单核细胞高簇是一个独立的不良生存预后因素(风险比:3.03;95% ci: 1.12-8.20;P = 0.029),并与免疫检查点阻断的预测应答降低相关。总之,原发性黑色素瘤肿瘤部位的m0 -巨噬细胞富集、淋巴细胞与单核细胞比例低的表型独立表征了一种侵袭性表型,可能对治疗有不同的反应。
{"title":"Prognostic value of intratumoral lymphocyte-to-monocyte ratio and M0 macrophage enrichment in tumor immune microenvironment of melanoma.","authors":"Neil K Jairath, Mark W Farha, Ruple Jairath, Paul W Harms, Lam C Tsoi, Trilokraj Tejasvi","doi":"10.2217/mmt-2020-0019","DOIUrl":"10.2217/mmt-2020-0019","url":null,"abstract":"<p><p>Skin cutaneous melanoma is characterized by significant heterogeneity in its molecular, genomic and immunologic features. Whole transcriptome RNA sequencing data from The Cancer Genome Atlas of skin cutaneous melanoma (n = 328) was utilized. CIBERSORT was used to identify immune cell type composition, on which unsupervised hierarchical clustering was performed. Analysis of overall survival was performed using Kaplan-Meier estimates and multivariate Cox regression analyses. Membership in the lymphocyte:monocyte<sup>low</sup>, monocyte<sup>hi</sup> <sup>gh</sup> and M0<sup>high</sup> cluster was an independently poor prognostic factor for survival (HR: 3.03; 95% CI: 1.12-8.20; p = 0.029) and correlated with decreased predicted response to immune checkpoint blockade. In conclusion, an M0-macrophage-enriched, lymphocyte-to-monocyte-ratio-low phenotype in the primary melanoma tumor site independently characterizes an aggressive phenotype that may differentially respond to treatment.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"7 4","pages":"MMT51"},"PeriodicalIF":1.0,"publicationDate":"2020-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/74/5f/mmt-07-51.PMC7727784.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38710349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is the neutrophil-to-lymphocyte ratio a useful prognostic indicator in melanoma patients? 中性粒细胞与淋巴细胞比值是黑色素瘤患者的有效预后指标吗?
IF 1 Q4 ONCOLOGY Pub Date : 2020-08-25 DOI: 10.2217/mmt-2020-0006
Joshua T Cohen, Thomas J Miner, Michael P Vezeridis

The neutrophil-to-lymphocyte ratio (NLR) is gaining traction as a biomarker with utility in a variety of malignancies including melanoma. Intact lymphocyte function is necessary for tumor surveillance and destruction, and neutrophils play a role in suppressing lymphocyte proliferation and in the induction of lymphocyte apoptosis. Early research in melanoma indicates that in high-risk localized melanoma, a high NLR is correlated with worse overall and disease-free survival. Similarly, in metastatic melanoma treated with both metastasectomy and immunotherapies, an elevated NLR is predictive of shortened overall survival and progression-free survival. Future studies incorporating NLR into more traditional melanoma prognostic markers while employing more granular outcomes, are needed to realize the full potential of NLR.

中性粒细胞与淋巴细胞比值(NLR)作为一种生物标志物,在包括黑色素瘤在内的多种恶性肿瘤中的应用正日益受到重视。完整的淋巴细胞功能是监控和摧毁肿瘤所必需的,而中性粒细胞在抑制淋巴细胞增殖和诱导淋巴细胞凋亡方面发挥作用。对黑色素瘤的早期研究表明,在高风险的局部黑色素瘤中,高 NLR 与较差的总生存期和无病生存期相关。同样,在接受转移灶切除术和免疫疗法的转移性黑色素瘤患者中,NLR升高预示着总生存期和无病生存期的缩短。未来的研究需要将 NLR 纳入更多传统的黑色素瘤预后指标,同时采用更精细的结果,以充分发挥 NLR 的潜力。
{"title":"Is the neutrophil-to-lymphocyte ratio a useful prognostic indicator in melanoma patients?","authors":"Joshua T Cohen, Thomas J Miner, Michael P Vezeridis","doi":"10.2217/mmt-2020-0006","DOIUrl":"10.2217/mmt-2020-0006","url":null,"abstract":"<p><p>The neutrophil-to-lymphocyte ratio (NLR) is gaining traction as a biomarker with utility in a variety of malignancies including melanoma. Intact lymphocyte function is necessary for tumor surveillance and destruction, and neutrophils play a role in suppressing lymphocyte proliferation and in the induction of lymphocyte apoptosis. Early research in melanoma indicates that in high-risk localized melanoma, a high NLR is correlated with worse overall and disease-free survival. Similarly, in metastatic melanoma treated with both metastasectomy and immunotherapies, an elevated NLR is predictive of shortened overall survival and progression-free survival. Future studies incorporating NLR into more traditional melanoma prognostic markers while employing more granular outcomes, are needed to realize the full potential of NLR.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"7 3","pages":"MMT47"},"PeriodicalIF":1.0,"publicationDate":"2020-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/17/53/mmt-07-47.PMC7475797.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38374924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pandemic medicine: the management of advanced melanoma during COVID-19. 大流行医学:COVID-19期间晚期黑色素瘤的管理。
IF 3.6 Q4 ONCOLOGY Pub Date : 2020-07-31 DOI: 10.2217/mmt-2020-0012
James R Patrinely, Douglas B Johnson
Amid the COVID-19 pandemic cancer patients present a unique challenge, as they are often immunosuppressed or subject to treatment-related toxicities that may cause severe disease manifestations. The practical impact of the COVID-19 pandemic on the management of advanced melanoma warrants further consideration. Restrictions on the US healthcare system to mitigate COVID-19 transmission have significantly altered melanoma management practices from the initial diagnosis of primary cutaneous disease to systemic treatment for advanced and metastatic presentations. We herein report our experience and recommendations for this patient population, highlighting the importance patient-centered planning based on tumor characteristics, resource availability and the local state of COVID-19 control.
{"title":"Pandemic medicine: the management of advanced melanoma during COVID-19.","authors":"James R Patrinely,&nbsp;Douglas B Johnson","doi":"10.2217/mmt-2020-0012","DOIUrl":"https://doi.org/10.2217/mmt-2020-0012","url":null,"abstract":"Amid the COVID-19 pandemic cancer patients present a unique challenge, as they are often immunosuppressed or subject to treatment-related toxicities that may cause severe disease manifestations. The practical impact of the COVID-19 pandemic on the management of advanced melanoma warrants further consideration. Restrictions on the US healthcare system to mitigate COVID-19 transmission have significantly altered melanoma management practices from the initial diagnosis of primary cutaneous disease to systemic treatment for advanced and metastatic presentations. We herein report our experience and recommendations for this patient population, highlighting the importance patient-centered planning based on tumor characteristics, resource availability and the local state of COVID-19 control.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"7 3","pages":"MMT45"},"PeriodicalIF":3.6,"publicationDate":"2020-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2020-0012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38374922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Methylated circulating tumor DNA as a biomarker in cutaneous melanoma. 甲基化循环肿瘤DNA作为皮肤黑色素瘤的生物标志物。
IF 3.6 Q4 ONCOLOGY Pub Date : 2020-07-30 DOI: 10.2217/mmt-2020-0010
Russell J Diefenbach, Jenny H Lee, Helen Rizos
The detection and monitoring of circulating tumor DNA (ctDNA) in melanoma using mutation-detection techniques such as droplet digital PCR and targeted next-generation sequencing (NGS) panels has been well documented (reviewed in [1]). In melanoma, baseline ctDNA assessment predicts overall survival of stage III patients and longitudinal assessment predicts response and survival of stage IV patients treated with immune checkpoint inhibitors and targeted therapies [2–4]. ctDNA can also be used to monitor the appearance of treatment-resistant melanoma subclones [2], tumor heterogeneity [5], metabolic tumor burden [6] and differentiates true progression from pseudoprogression in melanoma patients treated with immunotherapy [7]. ctDNA can be detected in approximately 34% of stage III melanoma and 73% of stage IV melanoma [2,4]. Several customized melanoma-associated NGS mutation panels for ctDNA have been described [8,9], and these panels are designed to detect greater than 80% of melanomas with mutant allele frequency detection limits of only 0.1%. These sequencing panels have several limitations, however. They often yield lower coverage of guaninecytosine (GC)-rich DNA regions, and these regions can be extremely informative cancer markers. For instance, the TERT gene has a GC-rich promoter that is mutated in approximately 70% of melanomas [8]. The complete sequencing of large genes (such as the NF1 gene at >8 kb) is also difficult as the increased gene coverage comes at the expense of overall mutation detection sensitivity. Moreover, the significance of many, low-frequency mutations can be unclear and alterations in some genes, including the TP53 tumor suppressor gene, may not reflect tumor biology, but rather clonal hematopoiesis, a common age-associated phenomenon involving the expansion of nucleated blood cells with somatic mutations [10]. An alternative liquid biopsy approach for monitoring cancer, without prior knowledge of somatic mutation profiles, involves the detection of epigenetic DNA changes, such as methylation. Methylation of cytosine residues within CpG islands is important for the regulation of gene expression and is altered during the development and progression of many cancers, including melanoma. Importantly, aberrant methylation of CpG-rich gene promoters can be a very consistent feature of cancer [11] and thus, the analysis of methylated DNA in liquid biopsies is a rapidly emerging area of interest [12]. Patterns of DNA methylation can change during melanoma progression and the analysis of DNA methylation can provide valuable information related to the phenotypic behavior and stage of melanoma [13]. The analysis of ctDNA methylation is challenging due to the low amounts and highly fragmented nature of ctDNA. Typically, most methylation analysis workflows incorporate an initial bisulfite conversion step which preserves methylated cytosines prior to downstream sequencing. With limited amounts of ctDNA, it is imperative that the ef
{"title":"Methylated circulating tumor DNA as a biomarker in cutaneous melanoma.","authors":"Russell J Diefenbach,&nbsp;Jenny H Lee,&nbsp;Helen Rizos","doi":"10.2217/mmt-2020-0010","DOIUrl":"https://doi.org/10.2217/mmt-2020-0010","url":null,"abstract":"The detection and monitoring of circulating tumor DNA (ctDNA) in melanoma using mutation-detection techniques such as droplet digital PCR and targeted next-generation sequencing (NGS) panels has been well documented (reviewed in [1]). In melanoma, baseline ctDNA assessment predicts overall survival of stage III patients and longitudinal assessment predicts response and survival of stage IV patients treated with immune checkpoint inhibitors and targeted therapies [2–4]. ctDNA can also be used to monitor the appearance of treatment-resistant melanoma subclones [2], tumor heterogeneity [5], metabolic tumor burden [6] and differentiates true progression from pseudoprogression in melanoma patients treated with immunotherapy [7]. ctDNA can be detected in approximately 34% of stage III melanoma and 73% of stage IV melanoma [2,4]. Several customized melanoma-associated NGS mutation panels for ctDNA have been described [8,9], and these panels are designed to detect greater than 80% of melanomas with mutant allele frequency detection limits of only 0.1%. These sequencing panels have several limitations, however. They often yield lower coverage of guaninecytosine (GC)-rich DNA regions, and these regions can be extremely informative cancer markers. For instance, the TERT gene has a GC-rich promoter that is mutated in approximately 70% of melanomas [8]. The complete sequencing of large genes (such as the NF1 gene at &gt;8 kb) is also difficult as the increased gene coverage comes at the expense of overall mutation detection sensitivity. Moreover, the significance of many, low-frequency mutations can be unclear and alterations in some genes, including the TP53 tumor suppressor gene, may not reflect tumor biology, but rather clonal hematopoiesis, a common age-associated phenomenon involving the expansion of nucleated blood cells with somatic mutations [10]. An alternative liquid biopsy approach for monitoring cancer, without prior knowledge of somatic mutation profiles, involves the detection of epigenetic DNA changes, such as methylation. Methylation of cytosine residues within CpG islands is important for the regulation of gene expression and is altered during the development and progression of many cancers, including melanoma. Importantly, aberrant methylation of CpG-rich gene promoters can be a very consistent feature of cancer [11] and thus, the analysis of methylated DNA in liquid biopsies is a rapidly emerging area of interest [12]. Patterns of DNA methylation can change during melanoma progression and the analysis of DNA methylation can provide valuable information related to the phenotypic behavior and stage of melanoma [13]. The analysis of ctDNA methylation is challenging due to the low amounts and highly fragmented nature of ctDNA. Typically, most methylation analysis workflows incorporate an initial bisulfite conversion step which preserves methylated cytosines prior to downstream sequencing. With limited amounts of ctDNA, it is imperative that the ef","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"7 3","pages":"MMT46"},"PeriodicalIF":3.6,"publicationDate":"2020-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2020-0010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38374923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Melanoma in pregnancy: certainties unborn. 妊娠期黑色素瘤:不确定因素。
IF 3.6 Q4 ONCOLOGY Pub Date : 2020-07-30 DOI: 10.2217/mmt-2020-0007
Enrico Zelin, Claudio Conforti, Roberta Giuffrida, Teresa Deinlein, Nicola di Meo, Iris Zalaudek

Melanoma diagnosed during childbearing period or up to 1 year after delivery is defined as pregnancy-associated melanoma (PAM). There is some evidence that PAM has worse prognosis if compared with melanoma in nonpregnant women, although literature is still inconclusive. Many biological mechanisms could explain this behavior, such as hormonal and immune status, increased lymphangiogenesis but also delay in diagnostic and therapeutic management. If PAM is suspected, a prompt excisional biopsy under local anesthesia can be performed regardless of the gestational period. Conversely, additional staging procedures (such as sentinel lymph node biopsy or imaging) and systemic therapy are still debatable during pregnancy. A multidisciplinary tailored approach should be preferred, together with exhaustive counseling of the mother.

在育龄期或产后一年内确诊的黑色素瘤被定义为妊娠相关黑色素瘤(PAM)。有证据表明,与非妊娠期妇女的黑色素瘤相比,妊娠相关性黑色素瘤的预后较差,但目前尚无定论。许多生物学机制可以解释这种情况,如荷尔蒙和免疫状态、淋巴管生成增加以及诊断和治疗管理的延迟。如果怀疑是 PAM,无论妊娠期长短,都可以在局部麻醉下及时进行切除活检。相反,在妊娠期进行额外的分期手术(如前哨淋巴结活检或成像)和全身治疗仍有争议。应首选多学科的定制方法,并对母亲进行详尽的咨询。
{"title":"Melanoma in pregnancy: certainties unborn.","authors":"Enrico Zelin, Claudio Conforti, Roberta Giuffrida, Teresa Deinlein, Nicola di Meo, Iris Zalaudek","doi":"10.2217/mmt-2020-0007","DOIUrl":"10.2217/mmt-2020-0007","url":null,"abstract":"<p><p>Melanoma diagnosed during childbearing period or up to 1 year after delivery is defined as pregnancy-associated melanoma (PAM). There is some evidence that PAM has worse prognosis if compared with melanoma in nonpregnant women, although literature is still inconclusive. Many biological mechanisms could explain this behavior, such as hormonal and immune status, increased lymphangiogenesis but also delay in diagnostic and therapeutic management. If PAM is suspected, a prompt excisional biopsy under local anesthesia can be performed regardless of the gestational period. Conversely, additional staging procedures (such as sentinel lymph node biopsy or imaging) and systemic therapy are still debatable during pregnancy. A multidisciplinary tailored approach should be preferred, together with exhaustive counseling of the mother.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"7 3","pages":"MMT48"},"PeriodicalIF":3.6,"publicationDate":"2020-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/4f/mmt-07-48.PMC7475795.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38374925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An update on GM-CSF and its potential role in melanoma management. GM-CSF及其在黑色素瘤治疗中的潜在作用的最新进展。
IF 3.6 Q4 ONCOLOGY Pub Date : 2020-07-29 DOI: 10.2217/mmt-2020-0011
Robert O Dillman

GM-CSF drives the differentiation of granulocytes and monocyte/macrophages from hematopoietic stem cell progenitors. It is required for differentiating monocytes into dendritic cells (DC). Although approved for recovery of granulocytes/monocytes in patients receiving chemotherapy, G-CSF is preferred. Enthusiasm for GM-CSF monotherapy as a melanoma treatment was dampened by two large randomized trials. Although GM-CSF has been injected into tumors for many years, the efficacy of this has not been tested. There is a strong rationale for GM-CSF as a vaccine adjuvant, but it appears of benefit only for strategies that directly involve DCs, such as intratumor talimogene laherparepvec and vaccines in which DCs are loaded with antigen ex vivo and injected admixed with GM-CSF.

GM-CSF驱动粒细胞和单核/巨噬细胞从造血干细胞祖细胞分化。它是单核细胞向树突状细胞(DC)分化所必需的。虽然已批准用于化疗患者的粒细胞/单核细胞恢复,但G-CSF是首选。两项大型随机试验抑制了对GM-CSF单一疗法作为黑色素瘤治疗的热情。虽然GM-CSF已被注射到肿瘤中多年,但其疗效尚未得到检验。GM-CSF作为疫苗佐剂有很强的理论依据,但它似乎只对直接涉及dc的策略有好处,例如肿瘤内的talimogene laherparepvec和将dc体外装载抗原并与GM-CSF混合注射的疫苗。
{"title":"An update on GM-CSF and its potential role in melanoma management.","authors":"Robert O Dillman","doi":"10.2217/mmt-2020-0011","DOIUrl":"https://doi.org/10.2217/mmt-2020-0011","url":null,"abstract":"<p><p>GM-CSF drives the differentiation of granulocytes and monocyte/macrophages from hematopoietic stem cell progenitors. It is required for differentiating monocytes into dendritic cells (DC). Although approved for recovery of granulocytes/monocytes in patients receiving chemotherapy, G-CSF is preferred. Enthusiasm for GM-CSF monotherapy as a melanoma treatment was dampened by two large randomized trials. Although GM-CSF has been injected into tumors for many years, the efficacy of this has not been tested. There is a strong rationale for GM-CSF as a vaccine adjuvant, but it appears of benefit only for strategies that directly involve DCs, such as intratumor talimogene laherparepvec and vaccines in which DCs are loaded with antigen <i>ex vivo</i> and injected admixed with GM-CSF.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"7 3","pages":"MMT49"},"PeriodicalIF":3.6,"publicationDate":"2020-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2020-0011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38374926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Laparoscopically assisted ilio-inguinal lymph node dissection versus inguinal lymph node dissection in melanoma. 腹腔镜辅助髂-腹股沟淋巴结清扫与黑色素瘤腹股沟淋巴结清扫。
IF 3.6 Q4 ONCOLOGY Pub Date : 2020-07-21 DOI: 10.2217/mmt-2019-0023
Enrique Boldo, Araceli Mayol, Rafael Lozoya, Alba Coret, Diana Escribano, Carlos Fortea, Andres Muñoz, Juan Carlos Pastor, Guillermo Perez De Lucia

Aim: Morbidity of open inguinal lymphadenectomy (OIL) is high. We use laparoscopy for pelvic time, preservation of the greater saphenous vein and transverse inguinal incisions (laparoscopically assisted ilio-inguinal lymphadenectomy, LIIL) to improve postoperative outcomes.

Patients & methods: Retrospective comparison of 14 patients who underwent LIIL and seven patients who underwent OIL.

Results: Fourteen LIIL compared with seven OIL showed a statistically significant reduction in morbidity (15.3 vs 75%) and hospital stay (7 vs 15.7 days). Pelvic lymph node involvement (27%) was not detected preoperatively. With a mean follow-up of 36.2 (range: 3-137) months, local recurrence rate was 58.3% in LIIL and 40% in OIL. Overall survival was significantly higher in OIL than in LIIL.

Conclusion: Compared with OIL, LIIL reduced postoperative complications and hospital stay.

目的:开放式腹股沟淋巴结切除术(OIL)的发病率高。我们使用腹腔镜检查盆腔时间,保留大隐静脉和腹股沟横切口(腹腔镜辅助髂-腹股沟淋巴结切除术,LIIL)来改善术后预后。患者与方法:回顾性比较14例LIIL患者和7例OIL患者。结果:14例LIIL与7例OIL相比,发病率(15.3 vs 75%)和住院时间(7 vs 15.7天)有统计学意义。术前未发现盆腔淋巴结受累(27%)。平均随访36.2个月(范围:3-137个月),LIIL和OIL的局部复发率分别为58.3%和40%。OIL患者的总生存率明显高于LIIL患者。结论:与OIL相比,LIIL减少了术后并发症和住院时间。
{"title":"Laparoscopically assisted ilio-inguinal lymph node dissection versus inguinal lymph node dissection in melanoma.","authors":"Enrique Boldo,&nbsp;Araceli Mayol,&nbsp;Rafael Lozoya,&nbsp;Alba Coret,&nbsp;Diana Escribano,&nbsp;Carlos Fortea,&nbsp;Andres Muñoz,&nbsp;Juan Carlos Pastor,&nbsp;Guillermo Perez De Lucia","doi":"10.2217/mmt-2019-0023","DOIUrl":"https://doi.org/10.2217/mmt-2019-0023","url":null,"abstract":"<p><strong>Aim: </strong>Morbidity of open inguinal lymphadenectomy (OIL) is high. We use laparoscopy for pelvic time, preservation of the greater saphenous vein and transverse inguinal incisions (laparoscopically assisted ilio-inguinal lymphadenectomy, LIIL) to improve postoperative outcomes.</p><p><strong>Patients & methods: </strong>Retrospective comparison of 14 patients who underwent LIIL and seven patients who underwent OIL.</p><p><strong>Results: </strong>Fourteen LIIL compared with seven OIL showed a statistically significant reduction in morbidity (15.3 vs 75%) and hospital stay (7 vs 15.7 days). Pelvic lymph node involvement (27%) was not detected preoperatively. With a mean follow-up of 36.2 (range: 3-137) months, local recurrence rate was 58.3% in LIIL and 40% in OIL. Overall survival was significantly higher in OIL than in LIIL.</p><p><strong>Conclusion: </strong>Compared with OIL, LIIL reduced postoperative complications and hospital stay.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"7 2","pages":"MMT42"},"PeriodicalIF":3.6,"publicationDate":"2020-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2019-0023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38294802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Melanoma Management
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1